Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $100M
Founded date: 2021
Investors 2
| Date | Name | Website |
| - | Access Bio... | accessbio-... |
| 16.10.2022 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.10.2022 | Series A | $100M | - |
Mentions in press and media 2
| Date | Title | Description |
| 17.10.2022 | Matchpoint Therapeutics Raises $100M in Series A and Seed Funding | Matchpoint Therapeutics, a Cambridge, MA-based biotechnology company, raised $100M in Series A and Seed funding. The $70M Series A round was led by Sanofi Ventures with participation from Atlas Venture, Access Biotechnology, Vertex Ventures... |
| - | Matchpoint Therapeutics | “Matchpoint aims to discover and develop precision small molecules that harness the power of covalency to bring new possibilities to the treatment of serious immune disease and cancer.” |